Core Scientific (NASDAQ: CORZ) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 78.26 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $115.244 million which beat the analyst consensus estimate of $111.254 million by 3.59 percent. This is a 44.92 percent increase over sales of $79.525 million the same period last year.